YOKNEAM, Israel, May 19 /PRNewswire/ -- Lumenis(R) Ltd., a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that doctors from four continents are meeting in Malaga, Spain to discuss and learn new laser techniques to treat enlarged prostate, also referred to as BPH (Benign Prostate Hyperplasia).
According to Avner Raz, President and CEO of Lumenis, “It is estimated by the U.S. National Institute of Health that BPH, or enlarged prostate, affects more than 50% of men over the age of 60, and 90% of men over the age of 80. As the global population ages, this condition impacts more and more men, which is one of the reasons so many physicians express significant interest in learning about less invasive alternatives to traditional surgery, such as transurethral resection of the prostate (TURP).”
“We are pleased to partner with Sigmacon (UK) Ltd. and Diagniscan S. A. to offer physicians from Europe, Asia, Africa and North America the opportunity to participate in this educational workshop,” continued Avner Raz. “At Lumenis, we strive to deliver advanced technology that enhances the lives of patients worldwide. We believe our innovative and versatile holmium laser system, the VersaPulse(R) PowerSuite(TM), is the answer these urologists seek for their patients. We hope they will fully participate in this workshop and carry home with them the confidence to integrate holmium into their practices -- in other words, offer these minimally-invasive and advanced techniques to their BPH patients.”
At this workshop, Dr. Peter Gilling (New Zealand) will lecture on and perform a live HoLEP(TM) holmium enucleation of the prostate procedure. When asked to cite the advantages of the holmium laser over TURP, Dr. Gilling told the Urology Times (Oct. 15, 2004), “HoLEP is better in every way compared to TURP. We have shown conclusively that it relieves obstruction better. It is more efficient. It takes more tissue, and we can take it out quicker. The morbidity is significantly less in terms of catheter time, hospital time, and bleeding complications.”
In addition, Dr. Richard Glowacki (United States) will lecture and perform a live HoLAP(TM) holmium ablation of the prostate procedure. Dr. Glowacki states, “When compared to TURP, HoLAP offers minimal bleeding, a shorter hospital stay -- typically as an outpatient, shorter catheter time, a similar surgical time, no TUR Syndrome (dilutional hyponatremia) and the ability to treat anticoagulated patients. HoLAP effectively debulks the prostate, which provides immediate results as well as a rapid return to normal activity.”
“Our holmium laser treatments use laser energy to relieve enlarged prostate symptoms by removing the tissue safely and effectively. In the end, it is the patient who truly benefits from these newer types of procedures,” concluded Avner Raz.
About Sigmacon (UK) Ltd.
Sigmacon has more than 25 years of experience marketing a wide range of therapeutic devices to the urological community in the U.K. The company has extensive experience in organizing workshops and seminars promoting the utilization of new technologies to enhance patient outcomes and grow clinical business for physicians. Sigmacon’s history of success includes technologies such as lasers and radiofrequency devices, with access to the majority of British clinics and hospitals where urology procedures are performed. For more information: http://www.sigmacon.co.uk
About Diagniscan S.A.
Founded in 1981, Diagniscan started distributing medical equipment and related disposables in 1984, including technical service. Diagniscan is highly recognized in the market for its products and its dedicated and specialized sales team. Diagniscan is located in Spain and a business unit of the CH- Werfen Hospital Group; an international holding of manufacturing and distribution companies providing high quality diagnostic and therapeutic medical devices. For more information: http://www.diagniscan.es/#
About Lumenis
Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto: http://www.lumenis.com
Investors: Lauri Hanover 1-866-232-6803 972-4-959-9122
Lumenis Ltd.
CONTACT: Lauri Hanover for Lumenis, 1-866-232-6803, +1-972-4-959-9122
